Metals and movement disorders

Current Opinion in Neurology

Volumn 26, Issue 4, 2013, Pages 435-441

  Taba, Pille ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

manganism; metal accumulation; neurodegeneration; neurodegeneration with brain iron accumulation; Wilson

Indexed keywords

ANTIPARKINSON AGENT; CERULOPLASMIN; COPPER; FATTY ACID; IRON; MANGANESE; METHCATHINONE; PANTOTHENATE KINASE 2;

ACERULOPLASMINEMIA; AUTOSOMAL RECESSIVE DISORDER; BETA PROPELLER PROTEIN ASSOCIATED NEURODEGENERATION; CHELATION THERAPY; CHOREOATHETOSIS; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DIFFUSION WEIGHTED IMAGING; FATTY ACID HYDROXYLASE ASSOCIATED NEURODEGENERATION; GASTROINTESTINAL ABSORPTION; GENE MAPPING; GENE MUTATION; GLOBUS PALLIDUS; HALLUCINATION; HUMAN; IRON BINDING CAPACITY; LIVER TRANSPLANTATION; MANGANISM; MENKES SYNDROME; MITOCHONDRIAL MEMBRANE PROTEIN ASSOCIATED NEURODEGENERATION; MOTOR DYSFUNCTION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANOID PSYCHOSIS; PARKINSON DISEASE; PHOSPHOLIPASE A26G ASSOCIATED NEURODEGENERATION; RESPIRATORY CHAIN; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; TREMOR; WILSON DISEASE; WOODHOUSE SAKATI SYNDROME;

BRAIN; CHELATION THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; METALS; MOVEMENT DISORDERS; NEURODEGENERATIVE DISEASES;

EID: 84880732901     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283629beb     Document Type: Review

References (67)

1. Martinez-Finley EJ, Gavin CE, Aschner M, Gunter TE. Manganese neurotoxicity and the role of reactive oxygen species. Free Radic Biol Med 2013; doi:10.1016/j.freeradbiomed.2013.01.032. [Epub ahead of print]
2. Racette BA, Aschner M, Guilarte TR, et al. Pathophysiology of manganeseassociated neurotoxicity. Neurotoxicology 2012; 33:881-886.
3. Roels HA, Bowler RM, Kim Y, et al. Manganese exposure and cognitive deficits: a growing concern for manganese neurotoxicity. Neurotoxicology 2012; 33:872-880.
4. Sikk K, Haldre S, Aquilonius SM, et al. Manganese-induced parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up. Eur J Neurol 2013; 20:915-920.
5. Djamshidian A, Sanotsky Y, Matviyenko Y, et al. Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism. Addiction 2013; 108:771-779.
6. Meyer-Baron M, Schäper M, Knapp G, et al. The neurobehavioral impact of manganese: results and challenges obtained by a meta-analysis of individual participant data. Neurotoxicology 2013; 36:1-9.
7. Selikhova M, Fedoryshyn L, Matviyenko Y, et al. Parkinsonism and dystonia caused by the illicit use of ephedrone: a longitudinal study. Mov Disord 2008; 23:2224-2231.
8. Criswell SR, Perlmutter JS, Huang JL, et al. Basal ganglia intensity indices and diffusion weighted imaging in manganese-exposed welders. Occup Environ Med 2012; 69:437-443.
9. Nelson G, Criswell SR, Zhang J, et al. Research capacity development in South African manganese mines to bridge exposure and neuropathologic outcomes. Neurotoxicology 2012; 33:683-686.
10. Sikk K, Haldre S, Aquilonius SM, Taba P. Manganese-induced Parkinsonism due to ephedrone abuse. Parkinsons Dis 2011; 2011:865319; doi:10.4061/2011/ 865319.
11. Tuschl K, Clayton PT, Gospe SM Jr, et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet 2012; 90:457-466.
12. Lucchini RG, Guazzetti S, Zoni S, et al. Tremor, olfactory and motor changes in Italian adolescents exposed to historical ferro-manganese emission. Neurotoxicology 2012; 33:687-696.
13. Abdalian R, Saqui O, Fernandes G, Allard JP. Effects of manganese from a commercial multitrace element supplement in a population sample of Canadian patients on long-term parenteral nutrition. JPEN J Parenter Enteral Nutr 2013; doi:10.117/0148607112454543. [Epub ahead of print]
14. Stepens A, Stagg JC, Platkajis A, et al. White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome. Brain 2010; 133: 3676-3684.
15. Carriere N, Rollin A, Simonin C, Lanbauge N. Acquired hepatocerebral degeneration revealed by neurogenic hyperventilation syndrome and myelitis. Neurol Neurosurg Psychiatry 2012; 83:999-1000.
16. Ferrara J, Jankovic J. Acquired hepatocerebral degeneration. J Neurol 2009; 256:320-322.
17. Erro R, Vitale C, Picillo M, et al. Early MRI findings in acquired hepatocerebral degeneration. Neurol Sci 2013; 34:589-591.
18. Kang JH, Tsai MC, Lin CC, et al. Increased risk of parkinsonism among patients with cirrhosis: a 7-year follow-up study. Liver Int 2011; 31:685-691.
19. Quadri M, Federico A, Zhao T, et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet 2012; 90:467-477.
20. Ribeiro RT, Dos Santos-Neto D, Braga-Neto P, Barsottini OG. Inherited manganism. Clin Neurol Neurosurg 2013; doi:10.1016/j.clineuro.2012. 12.032. [Epub ahead of print]
21. Brna P, Gordon K, Dooley JM, Price V. Manganese toxicity in a child with iron deficiency and polycythemia. J Child Neurol 2011; 26:891-894.
22. Stamelou M, Tuschl K, Chong WK, et al. Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder. Mov Disord 2012; 27:1317-1322.
23. Dewitt MR, Chen P, Aschner M. Manganese efflux in Parkinsonism: insights from newly characterized SLC30A10 mutations. Biochem Biophys Res Commun 2013; 432:1-4.
24. Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis 2012; 46:1-18.
25. Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov Disord 2012; 27:42-53.
26. Li A, Paudel R, Johnson R, et al. Pantothenate kinase-associated neurodegeneration is not a synucleinopathy. Neuropathol Appl Neurobiol 2013; 39:121-131.
27. Fermin-Delgado R, Roa-Sanchez P, Speckter H, et al. Involvement of globus pallidus and midbrain nuclei in pantothenate kinase-associated neurodegeneration: measurement of T2 and T2-time. Clin Neuroradiol 2013; 23:11-15.
28. Kostic VS, Svetel M, Mijajlovic M, et al. Transcranial sonography in pantothenate kinase-associated neurodegeneration. J Neurol 2012; 259:959-964.
29. Lim BC, Ki CS, Cho A, et al. Pantothenate kinase-associated neurodegeneration in Korea: recurrent R440P mutation in PANK2 and outcome of deep brain stimulation. Eur J Neurol 2012; 19:556-561.
30. Zorzi G, Zibordi F, Chiapparini L, et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord 2011; 26:1756-1759.
31. Paisan-Ruiz C, Li A, Schneider SA, et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 2012; 33:814-823.
32. Zhang P, Gao Z, Jiang Y, et al. Follow-up study of 25 Chinese children with PLA2G6-associated neurodegeneration. Eur J Neurol 2013; 20:322-330.
33. Schneider SA, Paisan-Ruiz C, Quinn NP, et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 2010; 25:979-984.
34. Kruer MC, Paudel R, Wagoner W, et al. Analysis of ATP13A2 in large neurodegeneration with brain iron accumulation (NBIA) and dystonia-parkinsonism cohorts. Neurosci Lett 2012; 523:35-38.
35. Brüggemann N, Hagenah J, Reetz K, et al. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 2010; 67:1357-1363.
36. Hogarth P, Gregory A, Kruer MC, et al. New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 2013; 80:268-275.
37. Schulte EC, Claussen MC, Jochim A, et al. Mitochondrial membrane protein associated neurodegeneration: a novel variant of neurodegeneration with brain iron accumulation. Mov Disord 2013; 28:224-227.
38. Alazami AM, Schneider SA, Bonneau D, et al. C2orf37 mutational spectrum in Woodhouse-Sakati syndrome patients. Clin Genet 2010; 78:585-590.
39. Kruer MC, Paisan-Ruiz C, Boddaert N. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 2010; 68:611-618.
40. Rupps R, Hukin J, Balicki M, et al. Novel mutations in FA2H-associated neurodegeneration: an underrecognized condition? J Child Neurol 2013; doi:10.1177/0883073812458538. [Epub ahead of print]
41. Haack TB, Hogarth P, Kruer MC, et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet 2012; 91:1144-1149.
42. Saitsu H, Nishimura T, Muramatsu K, et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet 2013; 45:445-449.
43. Kaneko K, Hineno A, Yoshida K, et al. Extensive brain pathology in a patient with aceruloplasminemia with a prolonged duration of illness. Hum Pathol 2012; 43:451-456.
44. Pan PL, Tang HH, Chen Q, et al. Desferrioxamine treatment of aceruloplasminemia: long-term follow-up. Mov Disord 2011; 26:2142-2144.
45. Storti E, Di Fabio R, Pierallini A, et al. De novo FTL mutation: a clinical, neuroimaging, and molecular study. Mov Disord 2013; 28:252-253.
46. Keogh MJ, Jonas P, Coulthard A, et al. Neuroferritinopathy: a new inborn error of iron metabolism. Neurogenetics 2012; 13:93-96.
47. Keogh MJ, Singh B, Chinnery PF. Early neuropsychiatry features in neuroferritinopathy. Mov Disord 2013; doi:10.1002/mds.25371. [Epub ahead of print]
48. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56:671-685.
49. Hofer H, Willheim-Polli C, Knoflach P, et al. Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study. J Hum Genet 2012; 57:564-567.
50. Dastsooz H, Dehghani SM, Imanieh MH, et al. A new ATP7B gene mutation with severe condition in two unrelated Iranian families with Wilson disease. Gene 2013; 514:48-53.
51. Geng J, Wang J, Yao RE, et al. Identification of one novel and nine recurrent mutations of the ATP7B gene in 11 children with Wilson disease. World J Pediatr 2012; 9:158-162.
52. Lee BH, Kim JH, Lee SY, et al. Distinct clinical courses according to presenting phenotypes and their correlations to ATP7B mutations in a large Wilson's disease cohort. Liver Int 2011; 31:831-839.
53. De Bem RS, Muzzillo AM, Deguti MM, et al. Wilson's disease in southern Brazil: a 40-year follow-up study. Clinics 2011; 66:411-416.
54. Carta MG, Sorbello O, Moro MF, et al. Bipolar disorders and Wilson's disease. BMC Psychiatry 2012; 12:52.
55. Frota NA, Barbosa ER, Porto CS, et al. Cognitive impairment and magnetic resonance imaging correlations in Wilson's disease. Acta Neurol Scand 2013; 127:391-398.
56. Vieira J, Oliveira PV, Juliano Y, et al. Urinary copper excretion before and after oral intake of D-penicillamine in parents of patients with Wilson's disease. Dig Liver Dis 2012; 44:323-327.
57. Prashant LK, Sinha S, Taly AB, Vasudev MK. Do MRI features distinguish Wilson's disease from other early onset extrapyramidal disorders? An analysis of 100 cases. Mov Disord 2010; 25:672-678.
58. Svetel M, Mijajlović M, Tomić A, et al. Transcranial sonography in Wilson's disease. Parkinsonism Relat Disord 2012; 18:234-238.
59. Ecevit C, Ozgenç F, Gö kçay F, et al. The diagnostic value of multimodal evoked potentials in the determination of subclinical neurological involvement of Wilson's disease. Eur J Gastroenterol Hepatol 2012; 24:627-632.
60. Walshe JM. The conquest of Wilson's disease. Brain 2009; 132:2289-2295.
61. Cortese A, Zangaglia R. Copper deficiency in Wilson's disease: peripheral neuropathy and myelodysplastic syndrome complicating zinc treatment. Mov Disord 2011; 26:1361-1362.
62. Da Silva-Jú nior FP, Machado AA, Lucato LT, et al. Copper deficiency myeloneuropathy in a patient with Wilson disease. Neurology 2011; 76:1673-1674.
63. Arnon R, Annunziato R, SchilskyM, et al. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. Clin Transplant 2011; 25:E52-E60.
64. Narumi S, Umehara M, Toyoki Y, et al. Liver transplantation for Wilson's disease in pediatric patients: decision making and timing. Transplant Proc 2012; 44:478-480.
65. Tümer Z. An overview and update of ATP7A mutations leading to Menkes disease and occipital horn syndrome. Hum Mutat 2013; 34:417-429.
66. Gandhi R, Kakkar R, Rajan S, et al. Menkes kinky hair syndrome: a rare neurodegenerative disease. Case Rep Radiol 2012; 2012:684309; doi:10. 1155/2012/684309.
67. Ogawa E, Kodama H. Effects of disulfiram treatment in patients with Menkes disease and occipital horn syndrome. J Trace Elem Med Biol 2012; 26:102-104.